Onkologie. 2017:11(4):200-204 | DOI: 10.36290/xon.2017.038

Current treatment management of metastatatic castration-resistant prostate cancer

Nikol Rušarová, Hana Študentová
Onkologická klinika, Fakultní nemocnice Olomouc

Recently there have been registered many new substances used in the treatment of metastatic castration-resistant prostate cancer.Due to the newest researches and knowledge breakthroughs in the field of mCRPC treatment, patients´prospects of long-termsurvival have been improving many times.

Keywords: metastatic castration-resistant prostate cancer, docetaxel, cabazitaxel, abiraterone, enzalutamide, immunotherapy,
radium-223, denosumab, zoledronic acid

Published: October 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rušarová N, Študentová H. Current treatment management of metastatatic castration-resistant prostate cancer. Onkologie. 2017;11(4):200-204. doi: 10.36290/xon.2017.038.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Epidemiologie zhoubných nádorů [online]. Masarykova univerzita, [2005], [cit. 2016-12-10]. Dostupný z WWW: http://www.svod.cz. ISSN 1802-8861.
    2. Sohn E. Screening: Diagnostic dilemma. Nature. 2015; 528(7582): S120-122. Go to original source... Go to PubMed...
    3. Giri VN, Beebe-Dimmer JL. Familial prostate cancer. Semin Oncol. 2016; 43(5): 560-565. Go to original source... Go to PubMed...
    4. Humphrey PA, et al. Histological variants of prostatic carcinoma and their significance. Histopatology. 2012; 60(1): 59-74. Go to original source... Go to PubMed...
    5. Mottet N, Bellmunt J, Briers E, et al. AU-ESTRO-SIOG Guidelines on Prostate Cancer. [cit. 2016-12-10]. Dostupné z: http://uroweb.org/wp-content/uploads/EAU-Guidelines-Prostate-Cancer-2016.pdf
    6. Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008; 26(2): 242-245. Go to original source... Go to PubMed...
    7. Petrylak DP, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351(15): 1502-1512. Go to original source... Go to PubMed...
    8. Di Lorenzo G, Buonerba C, Faiella A, et al. Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. BJU Int. 2011; 107: 234-239. Go to original source... Go to PubMed...
    9. Meisel A, von Felten S, Vogt DR, et al. Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial. Eur J Cancer. 2016; 56: 93-100. Go to original source... Go to PubMed...
    10. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.Lancet. 2010; 376(9747): 1147-1154. Go to original source... Go to PubMed...
    11. Kentepozidis N, Soultati A, Giassas S, et al. Paclitaxel in combination with carboplatin as salvage treatment in patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol. 2012; 70: 161-168. Go to original source... Go to PubMed...
    12. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012; 13(10): 983-992. Go to original source... Go to PubMed...
    13. Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015; 16(2): 152-160. Go to original source... Go to PubMed...
    14. Beer TM, Armstrong AJ, Rathkopf D, et al. Enzalutamide in Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. Eur Urol. 2017; 71(2): 151-154. Go to original source... Go to PubMed...
    15. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012; 367(13): 1187-1197. Go to original source... Go to PubMed...
    16. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010; 363(5): 411-422. Go to original source... Go to PubMed...
    17. Beer TM, Kwon ED, Drake CG, et al. Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. J Clin Oncol. 2017; 35(1): 40-47. Go to original source... Go to PubMed...
    18. Sartor O, Coleman R, Nilsson S, et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol. 2014; 15(7): 738-746. Go to original source... Go to PubMed...
    19. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002; 94(19): 1458-1468. Go to original source... Go to PubMed...
    20. Lipton A, Fizazi K, Stopeck AT, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer. 2012; 48(16): 3082-3092. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.